Jaffary Fariba, Nilforoushzadeh Mohammad Ali, Tavakoli Naser, Zolfaghari Behzad, Shahbazi Foroud
Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Adv Biomed Res. 2014 Mar 31;3:111. doi: 10.4103/2277-9175.129717. eCollection 2014.
Leishmaniasis is still one of the endemic parasitic infections in many countries comprising Iran. During the past decades, several medical and surgical approaches have been applied and studied to achieve the best option to treat the cutaneous leishmaniasis in Iran and the world. This study was carried out to evaluate the effect of topical Achilles millefolium in conjunction with intralesional glucantime on acute cutaneous leishmanial lesions.
sixty patients with confirmed acute cutaneous leishmaniasis were recruited in the study. Patients were randomly allocated into two groups to receive twice daily topical gel of Achilles millefolium 5% (containing 5% poly phenol) (group A) or placebo (group B) for four weeks along with weekly injection of intralesional Glucantime.
There was no significant difference between the two groups according to age, gender, and duration of the disease. Also, there was no significant difference in complete and relative cure rates between the two groups (P = 0.35) using Visual Analog Scale (VAS). Application site reactions were occurred in 12 patients including redness in 8 cases in group-A and 2 cases in group-B, severe itching in one case in group-A and increasing wound secretion in another case in group-A (P = 0.014).
Given the result of the present study, there is no significant difference in cure rates of lesions between yarrow and placebo topical gels as an adjuvant drugs with intralesional glucantime in treatment of acute cutaneous leishmanial lesions.
利什曼病仍是包括伊朗在内的许多国家的地方性寄生虫感染之一。在过去几十年中，已经应用并研究了多种医学和外科方法，以寻求治疗伊朗乃至全球皮肤利什曼病的最佳方案。本研究旨在评估外用蓍草与病灶内注射葡糖胺聚糖联合应用对急性皮肤利什曼病皮损的疗效。
本研究招募了60例确诊为急性皮肤利什曼病的患者。患者被随机分为两组，分别接受每日两次外用5%蓍草凝胶（含5%多酚）（A组）或安慰剂（B组），持续四周，并每周进行一次病灶内注射葡糖胺聚糖。
两组在年龄、性别和病程方面无显著差异。此外，使用视觉模拟量表（VAS）评估，两组的完全治愈率和相对治愈率也无显著差异（P = 0.35）。A组有12例出现用药部位反应，包括8例发红、1例严重瘙痒和1例伤口分泌物增加；B组有2例出现发红（P = 0.014）。
根据本研究结果，在治疗急性皮肤利什曼病皮损时，作为病灶内注射葡糖胺聚糖辅助药物的蓍草外用凝胶和安慰剂外用凝胶在治愈率方面无显著差异。
